3E Bioventures

3E Bioventures is a venture capital firm specializing in investments within the biotechnology sector, focusing on global health innovators. The firm actively invests in Biotech, including new drugs, new modalities, and drug discovery platforms, as well as in TechBio, the intersection of biology and technology that can potentially disrupt old paradigms. 3E Bioventures takes on a science-driven, entrepreneur-friendly investment philosophy by working closely with companies and research institutions to develop drugs or products that have strong unmet medical needs. The motto of 3E Bioventures Capital is captured in its name 3E: Expertise, Efficiency, Execution. Your Success Is Our Best Reward!

3E Bioventures has a history of investing in various biotech companies, including Acclaro Medical, Ansun BioPharma, Apexigen, Arnatar Therapeutics, C4 Therapeutics, Cardea Bio, Cytek Biosciences, Dewpoint Therapeutics, EpimAb Biotherapeutics, Larkspur Biosciences, MicuRx Pharmaceuticals, Myrobalan Therapeutics, OncoImmune, Profusa, Rapafusyn Pharmaceuticals, Refuge Biotechnologies, Regenacy Pharmaceuticals, Smartlens, Subtle Medical, among others. The firm has been involved in multiple funding rounds, with investments ranging from $1 million to $50 million.

The firm's investment strategy emphasizes a close collaboration with portfolio companies and research institutions to develop innovative solutions addressing significant medical needs. This approach reflects their commitment to advancing healthcare through strategic investments in cutting-edge biotech and TechBio sectors. Their motto, 'Expertise, Efficiency, Execution,' underscores their dedication to delivering impactful results in the healthcare industry.